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j.jmii.2015.08.019Methods: Medical records of HIV-infected Taiwanese patients seeking HIV care at a university
hospital from 2011 to 2014 were reviewed. The change of estimated glomerular filtration rate
(eGFR) was compared between patients not receiving combination antiretroviral therapy
(cART) and those starting cARTwith or without TDF. The determinants of annual eGFR changes
and factors associated with greater annual eGFR decline in TDF-exposed patients were
explored.
Results: A total of 775 patients were included: 140 were cART-naı¨ve, 393 received TDF-
containing cART, and 242 received cART without TDF. Compared with cART-naı¨ve patients,
the annual eGFR decline was greater in TDF-exposed patients (0.57  8.6 mL/min/1.73 m2
and 2.7  8.9 mL/min/1.73 m2, p Z 0.012). The annual eGFR decline between patients
receiving cART with or without TDF was similar (2.7  8.9 mL/min/1.73 m2 and
1.8  8.3 mL/min/1.73 m2, pZ 0.567). Diabetes was associated with worsening eGFR decline
in all studied patients. TDF exposure correlated with an additional annual eGFR decline of
2.73 mL/min/1.73 m2 (95% confidence interval 0.139e5.326, p Z 0.039) in patients with
CD4 count < 350 cells/mL. Among TDF-exposed patients, the factors associated with annual
eGFR decline of > 3 mL/min/1.73 m2 were higher baseline eGFR and lower CD4 counts.
Conclusion: Among HIV-infected Taiwanese patients, cART exposure correlated with the
decline of renal function. However, TDF-exposed patients are more likely to have prominent
eGFR decline, especially those with higher baseline eGFR, advanced HIV disease, and diabetes.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Tenofovir disoproxil fumarate (TDF) is a widely used
nucleotide reverse-transcriptase inhibitor, and is an
important component of combination antiretroviral therapy
(cART) for patients with human immunodeficiency virus
(HIV) infection.1,2 With the introduction of cART, survival of
HIV-infected patients has significantly improved. However,
aging, multiple comorbidities, complex medications, and
prolonged cART may increase the risk of kidney injury. In
recent years, kidney dysfunction has become a clinically
relevant and important issue.3e5
Since its introduction for clinical use, TDF has been
found to be associated with an increased risk of kidney
tubular dysfunction including Fanconi syndrome, diabetes
insipidus, or osteomalacia.6,7 Decline in renal function was
also reported in patients with exposure to TDF, experi-
encing either acute or chronic kidney injury, or merely a
decrease of estimated glomerular filtration rate (eGFR)
when compared with baseline values.8
The magnitude and clinical impact of TDF on renal func-
tion are still being debated. Variable degrees of eGFR loss
have been reported, ranging from < 5 mL/min/1.73 m2 to >
10 mL/min/1.73 m2 annually.8e10 In a 10-year longitudinal
prospective follow-up study, there was only a mild decline of
eGFR that was attributable to TDF.11 By contrast, a study on a
cohort of Japanese patients showed that the loss of eGFR
increased continuously for up to 5 years.12 Moreover,
increased frequency of proteinuria has been observed in pa-
tients receiving TDF-containing cART.13,14 Because protein-
uria may often precede GFR loss, measurements of
biomarkers, such as urine b-2-microglobulin, have been pro-
posed for early detection of renal tubular dysfunction.15
Previous studies have shown different incidences and
profiles of adverse effects of cART in Asian populationsang Y-S, et al., Kidney dysfunctio
ts, Journal of Microbiology, Icompared with those reported in Western countries.16,17
The predictive factors of TDF-related kidney injury have
been recognized, which vary among patients of different
ethnicities. For Asian people, a lower weight18,19 and
certain genetic variability20 may contribute to the devel-
opment of kidney injury. A few studies have reported on
the change in renal function in TDF-exposed Asians,19,21e24
however, most of the studies had short observation periods.
This study aimed to assess the eGFR changes and to identify
the risk factors for decline of renal function associated with
TDF exposure in HIV-1-infected Taiwanese patients.Methods
Patient population
This retrospective cohort study was conducted between
January 2011 and December 2014 at a university hospital
that is the largest designated hospital for HIV care in
Taiwan. Because TDF was not introduced into clinical use in
Taiwan until 2011, the study population included all HIV-
infected patients who regularly sought HIV care at the
hospital since 2011. Three groups of patients were defined
according to their treatment status: those not receiving
cART, those receiving TDF-containing cART, and those
receiving cART not containing TDF.
Patients were included if they were aged  20 years with
at least two serum creatinine measurements with an in-
terval of 90 days or more. The exclusion criteria included
receipt of ART < 90 days, intermittent or unknown duration
of ART exposure, and end-stage renal disease on dialysis.
ART was initiated and prescribed according to the national
treatment guidelines for HIV infection proposed by the
Taiwan Centers for Disease Control.25 The decision ton associated with tenofovir exposure in human immunodeficiency
mmunology and Infection (2015), http://dx.doi.org/10.1016/
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treating physicians. The study was approved by the
Research Ethics Committee of National Taiwan University
Hospital (registration number NTUH-201301041RIND). The
data were analyzed anonymously, and written or oral
informed consent was waived.
Data collection and evaluation of renal function
We used a standardized case record form to collect the
information on the demographics, sexual preference,
weight and height, comorbidity, treatment history of cART,
plasma HIV RNA load, CD4 lymphocyte count, concomitant
medications, and serum creatinine at the start of the study
from the medical records of the patients. Chronic kidney
disease was defined as an eGFR < 60 mL/min/1.73 m2.
Dyslipidemia was defined by regular use of lipid-lowering
agents, or a total cholesterol of  240 mg/dL, or a tri-
glycerides level of  200 mg/dL. Serum creatinine mea-
surements were performed every 6e12 months until the
study ended. All patients underwent annual proteinuria
screening. If the patients discontinued TDF due to renal
dysfunction, serum creatinine levels and urinalysis results
were monitored and followed up until the end of study
(December 31, 2014).
We used the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation, incorporating serum
creatinine, age, sex, and race as four parameters to esti-
mate GFR. The CKD-EPI equation was shown to be more
accurate than the Modification of Diet in Renal Disease
(MDRD) equation in the subgroup with GFR > 60 mL/min/
1.73 m2.26 Such populations include patients without kidney
disease and young patients, which are very much similar to
our study population. Guidelines published by the Kidney
Disease Improving Global Outcomes organization, managed
by the National Kidney Foundation of the United States,
recommends the CKD-EPI equation for patients with higher
GFR.27 Proteinuria, detected using spot urine sample, was
defined as > 1þ (i.e., urine protein level  30 mg/dL).
Our primary outcome of interest was the change of GFR
for each group of patients. The secondary objective was to
identify the risk factors associated with GFR decline in
patients with TDF exposure.
Statistical analysis
Patients’ demographics and basic characteristics were
evaluated by descriptive statistics. Data were presented as
mean (standard deviation) or count (percent). Categorical
variables were compared using chi-square test or Fisher
exact test. Continuous variables were compared using the
KruskaleWallis one-way analysis of variance or Man-
neWhitney U test. For data from two related samples,
variables were compared using paired t test. A two-tailed p
value < 0.05 was considered statistically significant. Fac-
tors associated with annual eGFR change in all patients
were identified using multivariate linear regression model.
Factors associated with annual eGFR decline by > 3 mL/
min/1.73 m2 in patients exposed to TDF were explored
using the multivariate logistic regression model. Variables
were entered into the model with a backward stepwisePlease cite this article in press as: Huang Y-S, et al., Kidney dysfunctio
virus-1-infected Taiwanese patients, Journal of Microbiology, Im
j.jmii.2015.08.019linear or logistic regression approach with p value < 0.1 as a
requirement for acceptance. Data were analyzed using
SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA).
Results
Clinical characteristics of patients
During the 4-year study period, a total of 775 HIV-infected
patients with available serial serum creatinine data over a
90-day interval were included for analysis: 140 were not
receiving cART, 393 had exposure to TDF-containing cART
(TDF-exposed group), and 242 received cART not containing
TDF (non-TDF-exposed group). The baseline characteristics
of the patients are shown in Table 1. Overall, most patients
were middle-aged homosexual men. The average weight of
patients was 66.6 kg. One fourth of the patients in the TDF-
exposed group had chronic hepatitis B virus infection. More
patients in the non-TDF-exposed group had diabetes mel-
litus, hypertension, dyslipidemia, and longer duration of
cART exposure with 80% of the regimens containing prote-
ase inhibitor(s). The mean follow-up duration of the pa-
tients was 672 days (standard deviation 292 days).
Renal function change of HIV patients exposed or
unexposed to tenofovir
The trends of changes in eGFR in each group of patients are
demonstrated chronologically by the timing of serum
creatinine tests in Figure 1. In the 4-year study period,
patients not starting cART had stable eGFR at around
110 mL/min/1.73 m2. By contrast, patients receiving cART
had significant decline of eGFR: a decline from 105.6 mL/
min/1.73 m2 to 97.6 mL/min/1.73 m2 in the TDF-exposed
group, and from 99.4 mL/min/1.73 m2 to 92.7 mL/min/
1.73 m2 in the non-TDF-exposed group (Figure 1).
In Table 2, we compared the changes between the first
and the last eGFR among the three groups. Both groups of
patients receiving cARTwith or without TDF had significantly
lower eGFR in the last measurements, compared with their
respective first eGFR measurements (105.6  16.4 mL/min/
1.73 m2 and 100.5  17.1 mL/min/1.73 m2; 99.4  17.6 mL/
min/1.73 m2 and 96.4  18.1 mL/min/1.73 m2, respectively;
both p < 0.001), however, patients not receiving cART had
similar levels (110.1  14.4 mL/min/1.73 m2 and
109.8  13.4 mL/min/1.73 m2; p Z 0.387). Compared with
patients not receiving cART, the annual decline of eGFR was
greater in the TDF-exposed group (0.57  8.6 mL/min/
1.73 m2 and 2.7  8.9 mL/min/1.73 m2; p Z 0.012). How-
ever, the annual declines of eGFR between the TDF-exposed
group and the non-TDF-exposed group were not statistically
significantly different (2.7  8.9 mL/min/1.73 m2 and
1.8  8.3 mL/min/1.73 m2; p Z 0.567). The annual per-
centage of decline in eGFR was 0.1  8.1% for the patients
not receiving cART, which was significantly lower than that
for the TDF-exposed group (2.3  8.6%, p Z 0.032) or the
non-TDF-exposed group (1.3  10.3%, p Z 0.035). A urine
specimen tested positive for proteinuria (protein
level  30 mg/dL) in 23.2% of the patients not receiving
cART, 13.9% of the patients in the TDF-exposed group, and
14.0% of the patients in the non-TDF-exposed group. Then associated with tenofovir exposure in human immunodeficiency
munology and Infection (2015), http://dx.doi.org/10.1016/
Table 1 Baseline characteristics of the HIV-infected patients with different treatment status.
Not on cART
(n Z 140)
cART experienced,
TDF exposed (n Z 393)
cART experienced, non-TDF
exposed (n Z 242)
P
Age (y) 31.5  7.3 38.2  10.0 43.4  12.3 <0.001
Male sex 131 (93.6) 379 (96.4) 230 (95.0) 0.345
MSM 115 (82.1) 330 (84.0) 172 (71.1) <0.001
Injecting drug user 15 (10.7) 6 (1.5) 5 (2.1) <0.001
Weight (kg) 67.8  14.1 65.9  10.7 67.0  11.4 0.63
BMI (kg/m2) 23.0  4.1 22.6  3.4 23.4  3.4 0.038
Comorbidity
HBsAg positive 12 (8.6) 100 (25.4) 30 (12.4) <0.001
Anti-HCV positive 28 (20) 37 (9.4) 10 (4.1) <0.001
Hypertension 6 (4.3) 37 (9.4) 40 (16.5) <0.001
Diabetes mellitus 5 (3.6) 15 (3.8) 21 (8.7) 0.018
CKD a 0 (0) 2 (0.5) 11 (4.5) <0.001
Malignancy 1 (0.7) 28 (7.1) 15 (6.2) 0.554
Heart failure 0 (0) 2 (0.5) 2 (0.8) 0.017
Years since HIV diagnosis 5.5  2.5 7.0  4.8 9.9  4.9 <0.001
Duration of ART (y) 0  0 5.9  4.6 9.1  4.9 <0.001
CD4 count (cells/mL) 541  173 374  291 547  258 <0.001
Plasma HIV RNA load
(log10 copies/mL)
3.96  0.8 3.3  1.9 1.70  0.9 <0.001
Exposed to PI 0 (0) 140 (35.6) 197 (81.4) <0.001
ACEI or ARB use 3 (2.1) 14 (3.6) 17 (7.0) 0.042
Dyslipidemia 2 (1.4) 18 (4.6) 49 (20.2) <0.001
Follow-up duration (d) 549  267 797  316 541  137 <0.001
a Defined as eGFR < 60 mL/min/1.73 m2.
Results are presented as n (%) or mean  standard deviation.
ACEIZ angiotensin II-converting enzyme inhibitor; ARBZ angiotensin II receptor blocker; BMIZ body mass index; cARTZ combination
antiretroviral therapy; CKD Z chronic kidney disease; eGFR Z estimated glomerular filtration rate; HCV Z hepatitis C virus;
HIV Z human immunodeficiency virus; MSM Z men who have sex with men; PI Z protease inhibitor; TDF Z tenofovir disoproxil
fumarate.
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patients not receiving cART than the TDF-exposed and non-
TDF-exposed groups (23.2% vs. 13.9%, p Z 0.032; 23.2% vs.
14.0%, pZ 0.035, respectively), but it was similar between
the TDF-exposed and the non-TDF-exposed groups (13.9% vs.
14.0%, p Z 0.524).
The factors influencing annual change of eGFR in HIV-
infected patients were explored by multivariate linear
regression (Table 3). The analysis indicated that presence
of diabetes mellitus and dyslipidemia would lead to greater
eGFR decrement annually at a rate of 5.01 mL/min/1.73 m2
[95% confidence interval (CI), 1.539e7.128, pZ 0.002] and
2.46 mL/min/1.73 m2 (95% CI, 0.838e6.177, p Z 0.010),
respectively. On the contrary, chronic kidney disease
(defined as eGFR < 60 mL/min/1.73 m2) and every addi-
tional CD4 cell count increase would lessen the annual
decrement of eGFR. TDF exposure had no significant influ-
ence on annual eGFR change.
In the subgroup analysis, we investigated the influence
of TDF exposure on the annual eGFR change in patients with
different CD4 levels using linear regression. In 277 patients
with CD4 count < 350 cells/mL, those exposed to TDF had
an additional 2.73-mL/min/1.73 m2 eGFR decrement
annually (95% CI 0.139e5.326; p Z 0.039). Diabetes melli-
tus continued to have a significant impact on eGFR decline
in this analysis (Table 3, Analysis 2).Please cite this article in press as: Huang Y-S, et al., Kidney dysfunctio
virus-1-infected Taiwanese patients, Journal of Microbiology, I
j.jmii.2015.08.019Factors associated with renal function decline in
patients with TDF exposure
Analysis of the risk factors associated with annual eGFR loss
>3 mL/min/1.73 m2 in 393 TDF-exposed patients is shown
in Table 4. In univariate analysis, factors associated with
annual eGFR loss >3 mL/min/1.73 m2 were increased
plasma HIV RNA load and higher baseline eGFR. Patients
with higher CD4 counts and longer TDF exposure appeared
to have a lower rate of annual eGFR loss >3 mL/min/
1.73 m2. In multivariate logistic regression, higher baseline
eGFR levels were associated with an increased risk of
annual eGFR loss > 3 mL/min/1.73 m2 [for every 10 mL/
min/1.73 m2 increase, odds ratio (OR) 1.292; 95% CI
1.123e1.486; p < 0.001], and higher CD4 counts were
protective against HIV RNA (for every 1 cell/mL increase, OR
0.999; 95% CI 0.998e1.000; p Z 0.008).
Outcomes of patients with TDF-related renal
failure
During the study period, 11 of 393 (2.8%) patients dis-
continued TDF. Six patients switched to other cART regi-
mens due to emergence of antiretroviral resistance, and
five (1.3%) patients withdrew TDF due to increased serumn associated with tenofovir exposure in human immunodeficiency
mmunology and Infection (2015), http://dx.doi.org/10.1016/
Figure 1. Trends of changes in estimated glomerular filtra-
tion rate (eGFR) in HIV-infected patients with three different
status of combination antiretroviral therapy (cART). The three
groups were as follows: patients not receiving cART [ART ()],
patients receiving TDF-containing cART [ART (þ), TDF (þ)],
and patients receiving cART not containing TDF [ART (þ), TDF
()]. The maximal follow-up duration was 48 months.
TDF Z tenofovir disoproxil fumarate.
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shown in Table 5. Their average eGFR at baseline was
74 mL/min/1.73 m2. At TDF discontinuation, the average
loss of eGFR was 32 mL/min/1.73 m2, and the average in-
crease of serum creatinine levels was 0.67 mg/dL. Three
patients had pre-existing hypertension or diabetes mellitus.
The other two patients had no chronic illness, but their
body mass indices were < 20 kg/m2. The serum creatinine
level of four patients recovered partially after TDF
discontinuation (median follow-up duration 161 days). The
only one patient with worsening renal function despite
discontinuation of TDF was the oldest, with poorly
controlled diabetes mellitus.
Discussion
In this Taiwanese cohort, the average annual decline of
eGFR in TDF-exposed patients was 2.7 mL/min/1.73 m2. In
multivariate analysis, TDF exposure was correlated with an
additional annual eGFR decrement of 2.73 mL/min/1.73 m2
in patients with CD4 count < 350 cells/mL. For patients
receiving TDF, the factors associated with annual eGFR
decrement > 3 mL/min/1.73 m2 were lower CD4 counts and
higher baseline eGFR in multivariate analysis. The preva-
lence of proteinuria was higher in patients not receiving
cART, but similar between patients receiving TDF- or non-
TDF-containing cART. During the 4-year study period, five
(1.3%) patients withdrew TDF due to deteriorating renal
function.Please cite this article in press as: Huang Y-S, et al., Kidney dysfunctio
virus-1-infected Taiwanese patients, Journal of Microbiology, Im
j.jmii.2015.08.019The first study in HIV-infected Asians to evaluate change
of creatinine clearance after TDF initiation was performed
in Thai patients.21 Using the CockcrofteGault formula and
MDRD formula, the authors concluded that creatinine
clearance remained stable after a median of 21 weeks of
TDF exposure. Later studies in HIV-infected Japa-
nese,12,18,23 Chinese,22 and Vietnamese28 patients all sug-
gested a harmful effect of TDF on renal function, yet
expressed the result in different ways, such as TDF expo-
sure shown to increase the risk of eGFR < 60 mL/min/
1.73 m2, eGFR > 10 mL/min/1.73 m2 or a 25% decline of
eGFR from baseline, or presence of urine markers for
proximal renal tubulopathy. Overall, these studies sug-
gested a higher risk for TDF-related renal dysfunction
among Asians than the patients in Western countries.
Few studies in Asian people calculated the eGFR changes
over time. Cao et al22 reported an 8.8-mL/min/1.73 m2
decline in eGFR at Week 48 in patients receiving both TDF
and protease inhibitors.22 Kinai and Hanabusa23 reported a
17-mL/min/1.73 m2 loss of eGFR at Week 96 in TDF-treated
patients. The degrees of eGFR decline in these two studies
are much greater compared with our observation. This
could be due to the difference in observation duration.
Several reports have found that eGFR of TDF-treated pa-
tients tends to decline rapidly within the first few months
of TDF exposure, and then stabilizes.22,29,30 It has been
suggested that changes in eGFR may be due to inhibition of
creatinine secretion of the proximal tubule due to TDF
exposure rather than due to actual damages to glomerular
functions.31 When patients are followed up for longer pe-
riods, the average annual decline in eGFR would be smaller.
Another factor leading to discrepancies in eGFR levels
among the different studies is the equation used to esti-
mate GFR. In HIV-infected patients with eGFR > 120 mL/
min/1.73 m2, MDRD may give higher mean eGFR estimates
than CKD-EPI.32
Advanced HIV disease, characterized by a low CD4 count
and high plasma HIV RNA load, had been recognized as a
predictor of TDF-related renal function decline.10 Current
guidelines suggest initiating cART in HIV-infected in-
dividuals with a CD4 count < 500 cells/mL, and as the pri-
ority, for patients who have a CD4 count < 350 cells/mL.1 In
our study, TDF exposure was associated with a 2.73-mL/
min/1.73 m2 eGFR decline annually in patients with CD4
count < 350 cells/mL. Our results suggest that more
frequent monitoring of renal function is needed in patients
with advanced HIV disease preparing for initiation of TDF-
based regimens. Among the factors that would increase
the risk of renal dysfunction in TDF-exposed patients, a
lower body weight is frequently mentioned in Asian pop-
ulations.18,28,33 The hypothesis is that a lower weight would
lead to a higher TDF plasma concentration, which increases
the risk of nephrotoxicity. A recent study measuring TDF
plasma concentration revealed that overexposure to TDF
was associated with a time-dependent decrease in eGFR.34
In multivariate analysis, we did not find a statistically sig-
nificant association between a lower weight and kidney
dysfunction. However, two of the five patients with no
comorbidity who discontinued TDF due to worsening renal
function in our study did have a low body mass index.
Our analyses showed TDF-exposed patients with higher
eGFR at baseline tend to have more prominent eGFR loss.n associated with tenofovir exposure in human immunodeficiency
munology and Infection (2015), http://dx.doi.org/10.1016/
Table 2 Renal function change and incidence of proteinuria of HIV-infected patients with different treatment status.
Not on cART
(n Z 140)
cART
experienced,
TDF exposed
(n Z 393)
cART
experienced,
TDF unexposed
(n Z 242)
Three
groups
p
Not on
cART vs.
TDF exposed
Not on
cART vs. TDF
unexposed
cART
experienced,
TDF vs. non-TDF
p
First serum
Cr (mg/dL)
0.89  0.14 0.89  0.18 0.91  0.18
Last serum
Cr (mg/dL)
0.88  0.13 0.93  0.19 0.94  0.22
First eGFR a
(mL/min/1.73 m2)
110.1  14.4 105.6  16.4 99.4  17.6
Last eGFR
(mL/min/1.73 m2)
109.8  13.4 100.5  17.1 96.4  18.1
Annual eGFR change
(mL/min/1.73 m2)
0.57  8.6 2.7  8.9 1.8  8.3 0.057 0.012 0.12 0.567
Annual eGFR
change (%)
0.1  8.1 2.3  8.6 1.3  10.3 0.059 0.032 0.035 0.524
Proteinuria
( 30 mg/dL)
23.2% (16/69) 13.9% (47/338) 14.0% (32/235) 0.115 0.052 0.055 0.922
a eGFR was calculated by CKD-EPI equation.
Results are n (%), or mean  standard deviation.
cART Z combination antiretroviral therapy; CKD-EPI Z Chronic Kidney Disease Epidemiology Collaboration; Cr Z creatinine;
eGFR Z estimated glomerular filtration rate; HIV Z human immunodeficiency virus; TDF Z tenofovir disoproxil fumarate.
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Horberg et al35 demonstrated that TDF-exposed patients
with a baseline eGFR > 80 mL/min/1.73 m2 had a more
pronounced eGFR loss than those with baseline eGFR be-
tween 50 mL/min/1.73 m2 and 79 mL/min/1.73 m2. A later
study from Japan found that high eGFR levels at baseline
was a risk factor for a decline in eGFR by > 25%.18 CKD
patients were expected to have faster decline of renal
function after initiating a nephrotoxic drug treatment. TheTable 3 Determinants of annual change of eGFR in HIV-infecte
Variable Univariate analysis
Regression coefficient (95% CI)
Analysis 1: All patients a (N Z 775)
Male sex 3.574 (6.493 to 0.600)
Diabetes mellitus 3.969 (6.698 to 1.241)
Chronic kidney disease 7.747 (2.997e12.497)
Dyslipidemia 1.986 (4.138 to 0.165)
CD4 count (cells/mL) 0.004 (0.002e0.007)
Tenofovir exposure 1.376 (2.600 to 0.151)
ACEI or ARB use 2.616 (5.608 to 0.377)
Analysis 2: Patients with CD4 < 350 (cells/mL)b (N Z 277)
Diabetes mellitus 13.862 (20.757 to 6.967)
Tenofovir exposure 2.246 (4.905 to 0.412)
a In analysis 1, univariate linear regression showed no significant cont
positivity, Anti-HCV-positivity, hypertension, congestive heart failure
inhibitor, and follow-up duration on eGFR (not listed in the table).
b In analysis 2, univariate linear regression showed no significant cont
positivity, Anti-HCV-positivity, chronic kidney disease, hypertension, c
ART, plasma HIV RNA load, exposure to protease inhibitor, and follow
ACEIZ angiotensin II-converting enzyme inhibitor; ARBZ angiotensin
CIZ confidence interval; eGFRZ estimated glomerular filtration rate
Please cite this article in press as: Huang Y-S, et al., Kidney dysfunctio
virus-1-infected Taiwanese patients, Journal of Microbiology, I
j.jmii.2015.08.019exact reason for these conflicting data is unclear. One
possible explanation is that by using the MDRD or CKD-EPI
formula, patients with high eGFR had greater eGFR
change than those with low eGFR in response to a same
level of serum creatinine elevation. To avoid this phe-
nomenon, methods that evaluate renal function directly,
such as 51Cr-EDTA clearance, might be more accurate.
Proteinuria was observed in a higher percentage of pa-
tients not receiving cART compared with the patientsd patients using multivariate linear regression.
Multivariate analysis
p Regression coefficient (95% CI) p
0.018
0.004 5.011 (7.768 to 2.254) <0.001
0.001 10.149 (5.403e14.895) <0.001
0.070 2.455 (4.610 to 0.301) 0.026
<0.001 0.005 (0.003e0.007) <0.001
0.028
0.087
<0.001 14.507 (21.389 to 7.625) <0.001
0.097 2.733 (5.326 to 0.139) 0.039
ribution (p > 0.1) of age, injective drug user, body weight, HBsAg-
, duration of cART, plasma HIV RNA load, exposure to protease
ribution (p > 0.1) of age, injective drug user, body weight, HBsAg-
ongestive heart failure, dyslipidemia, ACEI or ARB use, duration of
-up duration on eGFR (not listed in the table).
II receptor blocker; cARTZ combination antiretroviral therapy;
; HCVZ hepatitis C virus; HIVZ human immunodeficiency virus.
n associated with tenofovir exposure in human immunodeficiency
mmunology and Infection (2015), http://dx.doi.org/10.1016/
Table 4 Determinants of annual decline of eGFR by  3 mL/min/1.73 m2 in HIV-infected patients treated with tenofovir.
Annual decline of eGFR Univariate analysis Multivariate analysis
 3 mL/min/
1.73 m2 (n Z 146)
< 3 mL/min/
1.73 m2 (n Z 247)
OR (95% CI) p OR (95% CI) p
Age (Y) a 38.8  11.1 37.8  9.3 1.009 (0.989e1.030) 0.363
Male sex 143 (97.9) 236 (95.5) 2.222 (0.61e8.099) 0.226
Weight < 50 kg 11 (7.5) 13 (5.5) 1.423 (0.62e3.268) 0.406
HBsAg-positive 32 (21.9) 68 (27.5) 0.739 (0.457e1.196) 0.218
Anti-HCV-positive 11 (7.5) 26 (10.5) 0.693 (0.332e1.447) 0.328
Hypertension 17 (11.6) 20 (8.1) 1.496 (0.756e2.957) 0.247
Diabetes mellitus 8 (5.5) 7 (2.8) 1.988 (0.706e5.600) 0.194
Malignancy 11 (7.5) 17 (6.9) 1.102 (0.502e2.423) 0.808
Congestive
heart failure
1 (0.7) 1 (0.4) 1.697 (0.105e27.33) 0.709
Dyslipidemia 5 (3.4) 13(5.3) 0.638 (0.223e1.828) 0.403
CD4 count (cells/mL) a 308  294 412  282 0.999 (0.998e0.999) 0.004 0.999 (0.998e1.000) 0.008
HIV PVL
(log10 copies/mL)
a
3.6  1.9 3.1  1.8 1.156 (1.035e1.291) 0.010
Exposure to PI 54 (37.0) 86 (34.8) 1.099 (0.718e1.682) 0.665
ACEI or ARB use 6 (4.1) 8 (3.2) 1.280 (0.435e3.766) 0.653
Tenofovir
exposure (d) a
736  178 833  332 0.999 (0.998e1.000) 0.003 1.000 (0.999e1.000) 0.186
Baseline eGFR
(mL/min/1.73 m2) a
110.2  16.4 102.9  15.9 1.342 (1.168e1.542) <0.001 1.292 (1.123e1.486) <0.001
a For continuous variable in logistic regression, the odds ratios are shown for each 1-year increase in age, for each 1-cell/mL increase of
CD4 count, for each 1 log10 copy/mL increase of PVL, for each 1-day increase of TDF exposure, and for each 10-mL/min/1.73 m
2 increase
of baseline eGFR.
ACEIZ angiotensin II-converting enzyme inhibitor; ARBZ angiotensin II receptor blocker; CIZ confidence interval; eGFRZ estimated
glomerular filtration rate; HCV Z hepatitis C virus; HIV Z human immunodeficiency virus; OR Z odds ratio; PI Z protease inhibitor;
PVL Z plasma HIV RNA load; TDF Z tenofovir disoproxil fumarate.
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+ MODELreceiving cART in our study. This is not unexpected because
with the introduction of cART, there has been a decreasing
incidence of HIV-associated nephropathy. A previous study
also showed that cART initiation was associated with
improvement in proteinuria.37 Being a simple laboratory
test, urine dipstick test is recommended for screening
proteinuria in TDF-treated patients.38 One study that
included 10,841 HIV-infected patients reported that 1
additional year of TDF exposure was associated with 34%
increased risk of proteinuria.39 Limited by the small sample
size of our study, we did not find a statistically significant
difference in the prevalence of proteinuria between the
TDF-exposed and non-TDF-exposed groups.
Five (1.3%) patients withdrew TDF due to increased
serum creatinine levels during the study period. The
average increase in serum creatinine levels was 0.67 mg/dL
at TDF discontinuation. In a cohort study of 10,343 HIV-
infected patients receiving TDF-containing cART, 2.2% of
patients had an increase in serum creatinine levels of 
0.5 mg/dL, and 0.5% experienced a serious renal adverse
event of any type.40 A more recent study in Thailand re-
ported that 41 of 1204 (3.4%) TDF-treated patients had an
increase in serum creatinine level of  0.5 mg/dL from
baseline.41 Published guidelines suggest obtaining mea-
surements of serum creatinine levels consistently for TDF-
treated patients.38 However, there is no consensus on the
optimal timing to discontinue TDF in patients whose kidney
function declines progressively, and the best marker forPlease cite this article in press as: Huang Y-S, et al., Kidney dysfunctio
virus-1-infected Taiwanese patients, Journal of Microbiology, Im
j.jmii.2015.08.019TDF-related kidney injury has yet to be defined. After
discontinuation of TDF, four of the five patients in this study
had their eGFR partially recovered, which is in line with the
previous studies showing that the loss of renal function may
not be fully reversible with TDF withdrawal.42
There are several limitations of our study and our results
should be interpreted with caution. First, this is a retro-
spective study. Patients included in our study might not
have a uniform schedule of blood sampling, and their
adherence to cART might be incomplete. Second, although
we provided a relatively longer observation period than
previous studies in Asia,21,22 the duration of TDF exposure
was no more than 4 years. Because the pattern of eGFR
decline may not be linear, the changes of renal function in
the short-term observation period may not predict the long-
term clinical effect. Third, we did not examine other pa-
rameters representing renal tubular dysfunction, such as
glycosuria, urine phosphate, or urinary b2-microglobulin.
Likewise, we assessed proteinuria only qualitatively. Mea-
surement of microalbuminuria or urine protein-to-
creatinine ratio would more precisely reflect the urine
protein loss. Finally, HIV-infected women and patients with
a low eGFR comprised only a small proportion of our study
populations. Whether our findings can be generalized to
these patients warrants further investigations.
In conclusion, cART exposure correlated with the decline
of renal function among HIV-infected Taiwanese patients.
However, TDF-exposed patients are more likely to haven associated with tenofovir exposure in human immunodeficiency
munology and Infection (2015), http://dx.doi.org/10.1016/
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Please cite this article in press as: Huang Y-S, et al., Kidney dysfunctio
virus-1-infected Taiwanese patients, Journal of Microbiology, I
j.jmii.2015.08.019prominent eGFR decline, especially those with advanced
HIV disease (lower CD4 and high HIV RNA), diabetes melli-
tus, and higher baseline eGFR levels. Our results highlight
the importance of renal function monitoring when starting
TDF in patients initiating cART. As the survival rates of HIV-
infected patients are approaching that of the general
population in the cART era, the impact of prolonged TDF
exposure on renal function should be carefully monitored.Conflicts of interest
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